7TM Pharma is a biotech company that discovers and develops drugs with a primary therapeutic focus on diabetes, asthma, and more.
7TM Pharma is a biotech company that discovers and develops drugs with a primary therapeutic focus on diabetes, gastrointestinal, metabolic, asthma, and vascular diseases. The company offers seven transmembrane-spanning receptors, including TM38837, a small molecule CB1 receptor antagonist; TM30339, a NPY Y4 selective agonist that is used within gastrointestinal disorders, and short bowel syndrome; and CRTH2 antagonist, an oral drug for inflammatory or respiratory diseases.7TM Pharma was founded in 2000 and is based in Lyngby, Hovedstaden.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 12, 2007 | Series D | $22M | 1 | — | — | Detail |
Mar 31, 2006 | Series C | €19M | 1 | — | — | Detail |
Oct 28, 2004 | Series B | €6M | 1 | — | — | Detail |
Sep 27, 2001 | Series A | $15M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Dansk Innovation | — | Series D |
LODH Immunology Fund | — | Series A |